» Articles » PMID: 26839909

Imaging-genomic Pipeline for Identifying Gene Mutations Using Three-dimensional Intra-tumor Heterogeneity Features

Overview
Specialty Radiology
Date 2016 Feb 4
PMID 26839909
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

This paper presents an imaging-genomic pipeline to derive three-dimensional intra-tumor heterogeneity features from contrast-enhanced CT images and correlates them with gene mutation status. The pipeline has been demonstrated using CT scans of patients with clear cell renal cell carcinoma (ccRCC) from The Cancer Genome Atlas. About 15% of ccRCC cases reported have BRCA1-associated protein 1 (BAP1) gene alterations that are associated with high tumor grade and poor prognosis. We hypothesized that BAP1 mutation status can be detected using computationally derived image features. The molecular data pertaining to gene mutation status were obtained from the cBioPortal. Correlation of the image features with gene mutation status was assessed using the Mann-Whitney-Wilcoxon rank-sum test. We also used the random forests classifier in the Waikato Environment for Knowledge Analysis software to assess the predictive ability of the computationally derived image features to discriminate cases with BAP1 mutations for ccRCC. Receiver operating characteristics were obtained using a leave-one-out-cross-validation procedure. Our results show that our model can predict BAP1 mutation status with a high degree of sensitivity and specificity. This framework demonstrates a methodology for noninvasive disease biomarker detection from contrast-enhanced CT images.

Citing Articles

Advancements in Radiogenomics for Clear Cell Renal Cell Carcinoma: Understanding the Impact of BAP1 Mutation.

Greco F, DAndrea V, Buoso A, Cea L, Bernetti C, Zobel B J Clin Med. 2024; 13(13).

PMID: 38999524 PMC: 11242378. DOI: 10.3390/jcm13133960.


Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review.

Ferro M, Crocetto F, Barone B, Del Giudice F, Maggi M, Lucarelli G Ther Adv Urol. 2023; 15:17562872231164803.

PMID: 37113657 PMC: 10126666. DOI: 10.1177/17562872231164803.


Radiogenomics in Renal Cancer Management-Current Evidence and Future Prospects.

Ferro M, Musi G, Marchioni M, Maggi M, Veccia A, Del Giudice F Int J Mol Sci. 2023; 24(5).

PMID: 36902045 PMC: 10003020. DOI: 10.3390/ijms24054615.


Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions.

Khaleel S, Katims A, Cumarasamy S, Rosenzweig S, Attalla K, Hakimi A Cancers (Basel). 2022; 14(9).

PMID: 35565216 PMC: 9100795. DOI: 10.3390/cancers14092085.


Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.

Roussel E, Capitanio U, Kutikov A, Oosterwijk E, Pedrosa I, Rowe S Eur Urol. 2022; 81(5):476-488.

PMID: 35216855 PMC: 9844544. DOI: 10.1016/j.eururo.2022.01.040.


References
1.
Ganeshan B, Panayiotou E, Burnand K, Dizdarevic S, Miles K . Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol. 2011; 22(4):796-802. DOI: 10.1007/s00330-011-2319-8. View

2.
Ricketts C, Hill V, Linehan W . Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project. PLoS One. 2014; 9(1):e85621. PMC: 3893219. DOI: 10.1371/journal.pone.0085621. View

3.
Zinn P, Mahajan B, Majadan B, Sathyan P, Singh S, Majumder S . Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One. 2011; 6(10):e25451. PMC: 3187774. DOI: 10.1371/journal.pone.0025451. View

4.
Kapur P, Pena-Llopis S, Christie A, Zhrebker L, Pavia-Jimenez A, Rathmell W . Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 2013; 14(2):159-167. PMC: 4674067. DOI: 10.1016/S1470-2045(12)70584-3. View

5.
Joseph R, Kapur P, Serie D, Eckel-Passow J, Parasramka M, Ho T . Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer. 2014; 120(7):1059-67. PMC: 4075029. DOI: 10.1002/cncr.28521. View